Eculizumab

Complement Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Eculizumab is a drug in the Complement Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Complement Inhibitors. DrugCentral lists 1 molecular target, including C5. Recorded indications include Atypical hemolytic uremic syndrome, Congenital hemolytic uremic syndrome, Neuromyelitis optica and Paroxysmal nocturnal hemoglobinuria.

• Drug class: Complement Inhibitor.
• Mechanism of action: Complement Inhibitors.
• Molecular targets: C5 (1 listed in DrugCentral).
• Indications: Atypical hemolytic uremic syndrome, Congenital hemolytic uremic syndrome, Neuromyelitis optica, Paroxysmal nocturnal hemoglobinuria and Refractory generalized myasthenia gravis.
• ATC code: L04AJ01 (Complement inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Atypical hemolytic uremic syndrome
• Congenital hemolytic uremic syndrome
• Neuromyelitis optica
• Paroxysmal nocturnal hemoglobinuria
• Refractory generalized myasthenia gravis

Mechanism & targets

• Mechanism of action (MoA): Complement Inhibitors
• Established pharmacologic class: Complement Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Complement C5	C5	other	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2010-04-16	PMDA	—	Alexion Pharma	Yes
2007-06-20	EMA	—	—
2007-03-16	FDA	—	ALEXION PHARM

ATC classification

ATC code	Therapeutic hierarchy
L04AJ01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5
• FDA label: AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5
• HCSC label: AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Haemolysis	1798.4
Haemoglobin decreased	1014.4
Thrombotic microangiopathy	945.9
Blood lactate dehydrogenase increased	805.5
Haemoglobinuria	673.8
Off label use	631.4
Breakthrough haemolysis	619.2
Extravascular haemolysis	452.9
Myasthenia gravis crisis	314.2
Platelet count decreased	299.5
Chromaturia	290.0
Death	276.2

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 219685-50-4
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Eculizumab used for?

DrugCentral lists the following indications for Eculizumab: Atypical hemolytic uremic syndrome, Congenital hemolytic uremic syndrome, Neuromyelitis optica, Paroxysmal nocturnal hemoglobinuria and Refractory generalized myasthenia gravis.

How does Eculizumab work?

Eculizumab is classified as Complement Inhibitors; its molecular targets in DrugCentral include C5.

When was Eculizumab first approved?

Eculizumab was first approved by the FDA in 2007.

What drug class does Eculizumab belong to?

Eculizumab is in the Complement Inhibitor class.

Sources

• DrugCentral drug card 4969 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201828 — compound record and bioactivity
• DrugBank DB01257 — drug record
• FDA UNII A3ULP0F556 — substance identity
• DailyMed: FDA labels for Eculizumab — current prescribing information (label search)
• UniProt P01031 (C5) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.